Core Insights - Zoetis reported 2.21billioninrevenueforQ42023,an8.51.24 compared to 1.15ayearago[1]−TherevenueexceededtheZacksConsensusEstimateof2.19 billion by 1.04%, while EPS fell short of the consensus estimate of 1.33by6.771.21 billion, surpassing the average estimate of 1.19billion,reflectingan8.9270 million, exceeding the estimate of 248.25million,markinga4.3507 million, slightly below the estimate of 510.84million,butstillshowinga12.7982 million, above the estimate of 971.31million,representinga91.45 billion, slightly below the estimate of 1.47billion,withan11.1745 million, exceeding the estimate of 696.05million,reflectinga4.920 million, below the estimate of 25.39million,showingasignificantdeclineof25.9127 million, surpassing the estimate of 119.46million,witha10.488 million, exceeding the estimate of 55.62million,markingan11.41.36 billion, below the estimate of 1.44billion,withan11.1139 million, slightly above the estimate of 132.59million,reflectinga0.7401 million, exceeding the estimate of $346.82 million, representing a 6.4% year-over-year increase [2] Stock Performance - Over the past month, Zoetis shares returned -1.1%, while the Zacks S&P 500 composite increased by 5.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]